Author: Ravi Shankar

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — AIRE Inc., a Cayman Islands exempted company (“AIRE” or the “Company”) announced today that it has entered into an Agreement and Plan of Merger (the “Agreement”) with OceanLight Acquisition Corporation (“OceanLight”), a Cayman Islands exempted company and special purpose acquisition company, AIRE Global Group Inc., a Cayman Islands exempted company and wholly owned subsidiary of OceanLight (the “Purchaser”), and OCLT Merger Sub Ltd., a Cayman Islands exempted company and wholly owned subsidiary of the Purchaser (the “Merger Sub”), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of the Purchaser, and OceanLight will merge with and into the Purchaser, with the Purchaser surviving as the publicly traded company (the “Proposed Transaction”).

AIRE is a home textile and green sleep technology company dedicated to the development and global commercialization leveraging environmentally friendly advanced materials. The Company aims to provide customers with innovative and trusted sleep solutions while remaining committed to protecting the Earth’s ecological environment.

Daniel Khoo, Chief Executive Officer of AIRE, said, “We believe the Proposed Transaction represents an important milestone for AIRE as we continue to grow our textile trading business in the United States. Becoming a publicly traded company is expected to provide us with greater access to the capital markets and support our continued growth and development.” 

Ping Zhang, Chief Executive Officer of OceanLight, said, “We are pleased to partner with AIRE in this transaction. We believe AIRE’s textile trading business provides a strong foundation for its continued development, and we look forward to working together toward the completion of the transaction.”

Transaction Overview

Pursuant to the Agreement, OceanLight will merge with and into the Purchaser, its wholly owned subsidiary, with the Purchaser surviving the merger and becoming the publicly listed company, and the Purchaser’s wholly owned subsidiary, Merger Sub, will merge with and into AIRE, with AIRE surviving the merger as a wholly owned subsidiary of the Purchaser, in each case subject to the terms and conditions of the Agreement.

The Agreement provides for a Company Net Value of $1.0 billion. The number of Closing Payment Shares to be issued to the Company’s shareholders will be equal to the Company Net Value divided by $10.00. Additional information regarding the Proposed Transaction and pro forma ownership will be included in the registration statement and other transaction-related materials to be filed in connection with the Proposed Transaction.

The Proposed Transaction has been approved by the board of directors of OceanLight and duly authorized by AIRE, subject to the requisite shareholder approvals, and is subject to regulatory approvals and the satisfaction of certain other customary closing conditions, including, among others, the registration statement on Form F-4 being declared effective by the U.S. Securities and Exchange Commission (the “SEC”), the approval of the Proposed Transaction by the shareholders of OceanLight and AIRE, respectively, and the approval by Nasdaq of the additional listing application for the Closing Payment Shares.

The description of the Proposed Transaction contained herein is only a summary and is qualified in its entirety by reference to the Agreement relating to the Proposed Transaction. A more detailed description of the Proposed Transaction and a copy of the Agreement will be included in a Current Report on Form 8-K to be filed by OceanLight with the SEC and will be available on the SEC’s website at www.sec.gov. 

Advisors

Celine and Partners, P.L.L.C. serves as legal advisor to OceanLight. Torres & Zheng at Law, P.C. serves as legal advisor to AIRE. Chain Stone Capital Limited (CTM) is serving as financial advisor to AIRE.

About AIRE Inc.

AIRE is a home textile and green sleep technology company dedicated to the development and global commercialization leveraging environmentally friendly advanced materials. The Company aims to provide customers with innovative and trusted sleep solutions while remaining committed to protecting the Earth’s ecological environment.

About OceanLight Acquisition Corporation

OceanLight is a special purpose acquisition company incorporated as a Cayman Islands exempted company. OceanLight’s units are listed on the Nasdaq Global Market under the symbol OCLTU, and its ordinary shares, rights and warrants are listed on the Nasdaq Capital Market under the symbols OCLT, OCLTR and OCLTW, respectively. OceanLight was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Important Additional Information Regarding the Transaction Will Be Filed With the SEC

This press release relates to the proposed business combination between OceanLight and AIRE. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Purchaser intends to file a Registration Statement on Form F-4 (as may be amended from time to time) with the SEC, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all OceanLight shareholders. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. OceanLight and the Purchaser will also file other documents regarding the proposed business combination with the SEC. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF OCEANLIGHT ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by OceanLight and the Purchaser through the website maintained by the SEC at www.sec.gov. The documents filed in connection with the Proposed Transaction with the SEC also may be obtained free of charge upon written request to OceanLight, 1185 Avenue of the Americas, Suite 349, New York, NY 10036. 

Participants in the Solicitations

OceanLight, AIRE and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from OceanLight’s shareholders in connection with the proposed business combination. A list of the names of the directors, executive officers, other members of management and employees of OceanLight and AIRE, as well as information regarding their interests in the business combination, will be contained in the Registration Statement on Form F-4 to be filed with the SEC by Purchaser. Additional information regarding the interests of such potential participants in the solicitation process may also be included in other relevant documents when they are filed with the SEC. You may obtain free copies of these documents from the sources indicated above.

Caution About Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and section 21E of the U.S. Securities Exchange Act of 1934 (the “Exchange Act”) that are based on beliefs and assumptions and on information currently available to OceanLight and AIRE. These forward-looking statements are based on OceanLight’s and AIRE’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including projections of market opportunity and market share, the capability of AIRE to execute its business plans, including its plans to expand, the consideration to be issued in connection with the proposed business combination, anticipated benefits of the proposed business combination and expectations related to the terms and timing of the proposed business combination, are also forward-looking statements.

Although each of OceanLight and AIRE believes that it has a reasonable basis for each forward-looking statement contained in this communication, each of OceanLight and AIRE cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. These factors are difficult to predict accurately and may be beyond OceanLight’s and AIRE’s control. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form F-4 relating to the proposed business combination, which is expected to be filed by Purchaser with the SEC and other documents filed by OceanLight or the Purchaser from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements.

There may be additional risks that neither OceanLight nor AIRE presently knows or that OceanLight and AIRE currently believe are immaterial and that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by OceanLight or AIRE, their respective directors, officers or employees or any other person that OceanLight and AIRE will achieve their objectives and plans in any specified time frame, or at all. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for OceanLight or AIRE to predict these events or how they may affect OceanLight or AIRE. Except as required by law, neither OceanLight nor AIRE has any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur. Uncertainties and risk factors that could affect OceanLight’s and AIRE’s future performance and cause results to differ from the forward-looking statements in this release include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination; the outcome of any legal proceedings that may be instituted against OceanLight or AIRE, the combined company or others following the announcement of the business combination; the inability to complete the business combination due to the failure to obtain approval of the shareholders of OceanLight or AIRE or to satisfy other conditions to closing; changes to the proposed structure of the business combination that may be required or appropriate as a result of applicable laws or regulations; the ability to meet stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of OceanLight or AIRE as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; OceanLight’s estimates of expenditures and profitability and underlying assumptions with respect to shareholder redemptions; the impact of the COVID-19 pandemic; changes in laws and regulations that impact AIRE; ability to enforce, protect and maintain intellectual property rights; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in OceanLight’s final prospectus, dated August 7, 2026 and filed with the SEC on August 7, 2026, relating to its initial public offering and in subsequent filings with the SEC, including the registration statement on Form F-4 relating to the business combination expected to be filed by the Purchaser.

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

For further queries, please contact:

Ping Zhang
Chief Executive Officer
OceanLight Acquisition Corporation
Email: admin@oceanlightacq.com

Daniel Khoo
Chief Executive Officer
AIRE Inc.
Email: IR@aire-usa.com

TORTOLA, British Virgin Islands, Sept. 28, 2026 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company”) (TSX-V: ORC.A, ORC.B) provides an update regarding the previously announced sale of its Tanzanian business (the “Proposed Transaction”), the impending expiry of the Songo Songo Development Licence and related gas supply contracts, and the withdrawal of claims in the arbitration commenced by Swala Oil & Gas (Tanzania) Plc (in liquidation) and Swala UK Operations Limited.

Proposed Transaction

As previously disclosed, Orca entered into a Sale and Purchase Agreement with Taifa Gas Tanzania Limited (“Taifa”) and Amber Energy Investment L.L.C-FZ (“Amber”) pursuant to which Orca agreed to sell all of the outstanding shares of PAE PanAfrican Energy Corporation (“PAEM”), Orca’s Mauritian holding subsidiary through which Orca indirectly owns PanAfrican Energy Tanzania Limited (“PAET”). Upon closing of the Proposed Transaction, Taifa will acquire 49% of PAEM and Amber will acquire 51%.

The Proposed Transaction remains subject to the receipt of the required approvals and other closing conditions.

Songo Songo Licence and Operations

PAET’s Songo Songo Development Licence is scheduled to expire on October 10, 2026. Certain gas supply contracts associated with Songo Songo operations are also scheduled to expire on that date. PAET has advised customers, the Tanzania Petroleum Development Corporation (“TPDC”), and relevant regulatory authorities that uncertainty remains regarding whether the Proposed Transaction will complete prior to the licence expiry date.

PAET has communicated that two principal outcomes presently exist:

• completion of the Proposed Transaction and continuation of operations under new ownership; or
• cessation of PAET’s operation of the Songo Songo field and associated infrastructure following licence expiry, with transition activities undertaken in consultation with TPDC and applicable regulatory authorities.

In light of the uncertainty surrounding timing and regulatory approvals of the Proposed Transaction, PAET has recommended that TPDC, customers, and other stakeholders immediately advance transition planning activities, including operational familiarization and asset-mapping exercises, to facilitate an orderly transfer of responsibilities should the Proposed Transaction not complete before October 10, 2026.

The Company continues to support efforts to achieve an orderly outcome that maintains continuity of operations and natural gas supply.

Withdrawal of Swala Arbitration Claims

The Company has been advised that Swala Oil & Gas (Tanzania) Plc (in liquidation) and Swala UK Operations Limited (together, “Swala”) have formally withdrawn all claims, allegations, demands and causes of action asserted against Orca, PAEM, and PAET in the arbitration proceedings disclosed by the Company on February 27, 2026.

The arbitral tribunal has acknowledged receipt of the withdrawal by Swala and related correspondence. The Company and its counsel are assessing the procedural consequences of the withdrawal, including the Company’s request that the tribunal proceed to determine outstanding matters arising from the arbitration.

About Orca Energy Group Inc.

Orca is an international public company engaged in natural gas exploration, development and supply in Tanzania through its subsidiary PanAfrican Energy Tanzania Limited. Orca trades on the TSX Venture Exchange under the trading symbols ORC.A and ORC.B.

Forward-Looking Information

This news release contains forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities legislation. All information, other than historical fact included in this news release, which address activities, events or developments that Orca expects or anticipates to occur in the future, are forward-looking information. Forward-looking information often contains terms such as may, will, should, anticipate, expect, continue, estimate, believe, project, forecast, plan, intend, target, outlook, focus, could and similar words suggesting future outcomes. More particularly, this news release contains, without limitation, forward-looking information pertaining to the following: the expiration of the Songo Songo Development Licence and associated contracts, the potential outcomes communicated by PAET following the expiration of the Songo Songo Development Licence, the Company’s expectation to continue to engage with the TPDC and other stakeholders in relation to the Songo Songo Development Licence and associated contracts, the anticipated results of the Proposed Transaction, the completion of the Proposed Transaction and the timing thereof, the receipt of regulatory approvals and satisfaction of closing conditions of the Proposed Transaction, the potential cessation of PAET’s operation of the Songo Songo field and associated infrastructure, the potential continued operation of the Songo Songo field following the completion of the Proposed Transaction, transition activities for the Songo Songo field and associated infrastructure subsequent to the licence expiry, and the potential outcomes of the withdrawal of all claims by Swala in the arbitration proceedings.

Such forward-looking information is based on certain assumptions made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors the Company believes are appropriate in the circumstances, including, but not limited to: the value, costs, and liabilities associated with the Songo Songo field and associated infrastructure and the Company and shareholders’ exposure thereto; that the outcomes communicated by PAET regarding the expiration of the Songo Songo Development Licence are likely and reasonable; the ability of the Company to continue its operating activities subsequent to the expiration of the Songo Songo Development Licence and associated contracts; the current status of the Company’s relationship with the TPDC and other stakeholders; the ability of the Company, Taifa, and Amber to satisfy the closing conditions of the Proposed Transaction; the receipt of regulatory approvals for the Proposed Transaction; the actions of the arbitral tribunal resulting from Swala’s withdrawal from the arbitration proceedings; the anticipated supply and demand of natural gas are in line with the Company’s expectations; that the Company will have sufficient cash flow, debt or equity sources or other financial resources required to fund its capital and operating expenditures and requirements as needed; availability of skilled labor; effects of regulation by governmental agencies; current or, where applicable, proposed industry conditions, laws and regulations will continue in effect or as anticipated as described herein; and other matters.

Actual results may differ materially from those anticipated in the forward-looking information. Risks and uncertainties that could cause actual results to differ materially include, without limitation: the risk that the Songo Songo Development Licence and associated contracts expire prior to completion of the Proposed Transaction; uncertainty regarding the operating environment of PAET and continued operation of the Company subsequent to the expiry of the Songo Songo Development Licence and associated contracts; that the TPDC and other stakeholders may not continue to engage with the Company regarding the Songo Songo Development Licence and associated contracts; that the outcomes communicated by PAET regarding the expiry of the Songo Songo Development Licence are not the only outcomes; that the satisfaction of closing conditions and receipt of regulatory approvals of the Proposed Transaction may require commercial concessions or other arrangements that are unacceptable to one or more of the parties to the Proposed Transaction; the risk that the Proposed Transaction is not completed on terms anticipated or at all; uncertainties regarding actions of the arbitral tribunal following Swala’s withdrawal from the arbitration proceedings; occurrence of circumstance or events which significantly impact the Company’s cash flow and liquidity and the Company’s ability cover its long-term and short-term obligations or fund planned capital expenditures; the impact of general economic conditions in the areas in which the Company operates; civil unrest; changes in laws and regulations including the adoption of new laws and regulations; availability of qualified personnel or management; fluctuations in commodity prices, foreign exchange or interest rates; risks associated with negotiating with foreign governments; and risks and uncertainties associated with oil and gas operations. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, it cannot guarantee future results and performance or achievement since such expectations are inherently subject to significant business, economic, operational, competitive, political and social uncertainties and contingencies.

The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information please contact:
Jay Lyons
Chief Executive Officer
+44 (0)20 8434 2754
ir@orcaenergygroup.com

David W. Ross
Chair and Non-Executive Director
+1 (403) 830-2455
dross7915@gmail.com

For media enquiries:
Celicourt (PR)
Mark Antelme
Orca@celicourt.uk
+44-20 8434 2643

ROANOKE, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) — The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company’s common stock. The dividend will be paid on November 2, 2026 to shareholders of record on October 16, 2026. This is the Company’s 330th consecutive quarterly cash dividend. 

RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Midstream, LLC. 

The statements in this release that are not historical facts constitute “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause the Company’s actual results and experience to differ materially from any expectations expressed in the Company’s forward-looking statements, regarding customer growth, infrastructure investment and margins. These risks and uncertainties include inflation, gas prices and supply, geopolitical considerations and regulatory and legal challenges along with risks included under Item 1A in the Company’s fiscal 2025 Form 10-K, as well as an updated risk within Item 1A in the Company’s March 31, 2026 Form 10-Q. Forward-looking statements reflect the Company’s current expectations only as of the date they are made. The Company assumes no duty to update these statements should expectations change or actual results differ from current expectations except as required by applicable laws and regulations.

Past performance is not necessarily a predictor of future results.

Contact:                                  Telephone:

Timothy J. Mulvaney Vice President, Treasurer and CFO 540-777-3997

• First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United States
• Egetis launches Egetis RareLink™, the EMCITATE patient support program, in partnership with PANTHERx® Rare
• FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the approval
• Egetis to host a conference call and webcast for analysts and investors on Tuesday September 29 at 8:00 am CEST (2:00 am EDT)

STOCKHOLM, SWEDEN, Sept. 28 2026. (GLOBE NEWSWIRE) – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.

MCT8 deficiency is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid-hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. As a result, patients experience disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This leads to a complex disorder characterized by severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years. For further details, please see ‘About MCT8 deficiency’ below.

The FDA approval of EMCITATE was supported by a comprehensive clinical development program evaluating EMCITATE in patients with MCT8 deficiency, including ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Center (EMC) Cohort Study, EMC Survival Study and the U.S. Expanded Access Program.  

“Today marks a turning point for patients living with MCT8 deficiency and their caregivers, who have waited long for an approved treatment in the United States. Our immediate focus is ensuring that eligible patients can access EMCITATE as quickly as possible,” said Nicklas Westerholm, Chief Executive Officer of Egetis Therapeutics. “We are deeply grateful to the patients, caregivers, investigators, clinicians, and advocacy organizations whose partnership and determination made this achievement possible as well as all Egetis employees and collaborators for their dedicated and hard work. Today also marks a defining milestone for Egetis as we take steps forward in developing medicines that address serious unmet medical needs for patients with rare diseases.”

 “Through my experience caring for patients with MCT8 deficiency, I have seen firsthand the profound impact this complex and life-limiting disorder can have on patients and their families. Early diagnosis is critical so that patients can be appropriately evaluated, connected with specialists and receive coordinated multidisciplinary care. The FDA approval of EMCITATE provides physicians in the United States with the first approved treatment option for patients and represents an important advance for the MCT8 deficiency community,” said Andrew J. Bauer, M.D., a pediatric endocrinologist and expert in thyroid hormone disorders and Principal Investigator in ReTRIACt trial and Triac Trial II, evaluating EMCITATE in MCT8 deficiency.

“The FDA approval of EMCITATE is a historic milestone for the MCT8 deficiency community and an important step toward ensuring patients have access to a treatment. We are grateful to Egetis and to the researchers, clinicians, patients, families, and advocates whose dedication helped bring this treatment to patients. This approval is a testament to what is possible when a community comes together with a shared commitment to advancing care. We look forward to continuing to advocate for patients and supporting efforts to expand awareness, access and treatment options for the worldwide MCT8 community.” said the MCT8-AHDS Foundation.

Launch of Egetis RareLink™: EMCITATE® comprehensive patient support program

Egetis is committed to helping eligible patients gain timely access to EMCITATE. The Company expects EMCITATE to be commercially available in the United States in eight to ten weeks post approval. Through Egetis RareLink, its dedicated patient support program, Egetis has established the access infrastructure—including specialty distribution and dedicated support resources—to help ensure a seamless experience for patients, caregivers, and healthcare professionals from day one. As part of its U.S. commercialization strategy, Egetis has partnered with PANTHERx® Rare to support medication access, education, care coordination and ongoing treatment services. For more information about Egetis RareLink, call 1-844-4EGETIS (1-844-434-3847).

Priority review voucher granted

In connection with the approval of EMCITATE, the FDA granted Egetis a Rare Pediatric Disease Priority Review Voucher (PRV).  The Company currently expects to explore monetization of the PRV, which could potentially occur in the fourth quarter of 2026, subject to market conditions.

Conference call and webcast information

Egetis will host a conference call and webcast for analysts and investors to discuss the FDA approval of EMCITATE beginning at 8:00 am CEST (2:00 am EDT) on Tuesday, September 29, 2026.

Webcast link: https://live.events.inderes.com/fda-approval-sep-2026  

Teleconference link: https://events.inderes.com/live/fda-approval-sep-2026/dial-in   

After registration to the teleconference you will be provided phone numbers and a conference ID to access the call. You can ask questions verbally via the teleconference. A replay of the webcast can be accessed via the webcast link above.

About MCT8 deficiency

Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the SLC16A2 gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. As a result, patients experience disrupted thyroid hormone signaling, characterized by insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This leads to a complex disorder characterized by severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis.

The elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver, and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance, and increased susceptibility to infections. These systemic consequences of persistent thyrotoxicosis are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.

For more information about MCT8 deficiency, please visit MCT8deficiency.com or LifewithMCT8deficiency.com

INDICATION AND USAGE

EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome).

Limitation of use: EMCITATE is not recommended for the treatment of primary hypothyroidism.

IMPORTANT SAFETY INFORMATION

BOXED WARNING
NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

CONTRAINDICATIONS
Primary hyperthyroidism

WARNINGS AND PRECAUTIONS
Thyrotoxicosis: Signs and symptoms of thyrotoxicosis (e.g., increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia, nightmares) have occurred with EMCITATE during treatment initiation and dose titration. Monitor and adjust the EMCITATE dose as indicated.
Laboratory Test Interference for T3 Measurement: Tiratricol can cross-react with immunoassays for T3 leading to unreliable T3 results and cause an overestimation of T3.

ADVERSE REACTIONS
Most common adverse reactions (≥ 5%): diarrhea, vomiting, rash, and hyperhidrosis.

To report SUSPECTED ADVERSE REACTIONS, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information here: https://www.egetis.com/wp-content/uploads/emcitate-full-prescribing-information.pdf

About Egetis Therapeutics

Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company’s lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and now in the United States. Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.

For more information, visit egetis.com and follow the Company on LinkedIn.

About PANTHERx Rare 

PANTHERx Rare makes rare disease care more hyper-personalized and less overwhelming by focusing relentlessly on each patient and each therapy. PANTHERx experts develop deep personal relationships with patients, prescribers, and pharmaceutical partners, serving as trusted advocates to ensure seamless collaboration and exceptional care. Since its founding in a garage in Pittsburgh, PA in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S., leveraging established-company resources while maintaining small-company responsiveness, innovation, and attention to detail.

PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual accreditations in rare disease from the Accreditation Commission for Health Care (ACHC) and Utilization Review Accreditation Commission (URAC). PANTHERx is also the nine-time winner of the prestigious MMIT Patient Choice Award for patient satisfaction, including the 2026 honor.

For more information, please email TheRareSP@pantherxrare.com or visit www.pantherxrare.com

Contacts

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com
+46 (0) 733 542 062

Karl Hård, Head of Investor Relations, Communications & Business Development
karl.hard@egetis.com
+46 (0) 733 011 944

This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:46 pm CEST on September 28, 2026.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE® (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company’s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company’s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as “expects,” “anticipates,” “intends,” “believes,” “estimates,” “plans,” “will,” “may,” “could,” “potential,” or similar expressions, although not all forward-looking statements contain these words.
These statements are based on the Company’s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company’s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.
For a further description of risks and uncertainties that could affect the Company’s business and results, reference is made to the Company’s most recent annual report and other filings with relevant regulatory authorities available at www.egetis.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.

NEW YORK, September 28, 2026 — 21shares, one of the world’s largest issuers of cryptocurrency exchange traded funds (ETFs), today announced the following shareholder distributions for the 21shares Ethereum Staking ETF (TETH), 21shares Solana Staking ETF (TSOL), 21shares Hyperliquid Staking ETF (THYP), 21shares Sui Staking ETF (TSUI), and 21shares Polkadot Staking ETF (TDOT). Distributions consist of staking rewards earned from staked ETH, SOL, HYPE, SUI, and DOT tokens by each fund, respectively.

Ticker	Name	Distribution	Ex/Record date	Payable date
TETH	21shares Ethereum Staking ETF	$0.031602	9/29/2026	9/30/2026
TSOL	21shares Solana Staking ETF	$0.076590	9/29/2026	9/30/2026
THYP	21shares Hyperliquid Staking ETF	$0.191360	9/29/2026	9/30/2026
TSUI	21shares Sui Staking ETF	$0.052939	9/29/2026	9/30/2026
TDOT	21shares Polkadot Staking ETF	$0.045029	9/29/2026	9/30/2026

About 21shares

21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building a seven-year track record of creating crypto ETPs that are listed on some of the biggest, most liquid securities exchanges globally. Backed by a specialized research team, proprietary technology, and deep capital markets expertise, 21shares delivers innovative, simple and cost-efficient investment solutions.

21shares is a subsidiary of FalconX, one of the world’s largest digital asset prime brokers. 21shares maintains independent operations from FalconX while strategically leveraging the resources and reach of FalconX to accelerate its mission and unlock new growth. For more information, please visit www.21shares.com.

Media Contact
Audrey Belloff: audrey.belloff@21Shares.com
Alethea Jadick: ajadick@sloanepr.com

Important Information

The 21shares Ethereum Staking ETF (TETH), 21shares Solana Staking ETF (TSOL), 21shares Sui Staking ETF (TSUI), 21shares Polkadot Staking ETF (TDOT), and 21shares Hyperliquid Staking ETF (THYP) (referred to collectively as the “Trusts”), are not registered under the Investment Company Act of 1940 (the “40 Act”) and therefore are not subject to the same regulations and protections as 40 Act registered ETFs and mutual funds. Investing involves significant risk, including possible loss of principal. An investment in the Trusts is subject to a high degree of risk and heightened volatility and not suitable for all investors. The Trusts are not suitable for an investor who cannot afford the loss of the entire investment. An investment in the Trusts is not a direct investment in ETH, SOL, SUI, DOT, or HYPE.

Investing involves significant risk, including the possible loss of principal. There is no assurance that the Trusts will generate a profit for investors.

Ethereum, Solana, Sui, Polkadot, and Hyperliquid are relatively new asset classes, and the market for these assets is subject to rapid changes and uncertainty. Ethereum, Solana, Sui, Polkadot, and Hyperliquid are largely unregulated and these investments may be more susceptible to fraud and manipulation than more regulated investments.

Must be preceded or accompanied by the prospectuses for TETH (here), TSOL (here), TSUI (here), TDOT (here), and THYP (here).

The Trusts participate in staking a portion of their holdings in order to generate additional rewards. Staking involves committing assets to support the operations of a blockchain and, in return, may provide rewards to the relevant Trusts. While staking can potentially enhance returns, it also introduces additional risks, including operational, technological, regulatory, and counterparty risks. Staking Ethereum, Solana, Polkadot, Sui, or Hyperliquid introduces several risks, including the possibility of losing staked Ethereum, Solana, Polkadot, Sui, or Hyperliquid through penalties, slashing, or inactivity leaks if validators behave poorly, go offline, or violate protocol rules. Staked Ethereum, Solana, Polkadot, Sui, and Hyperliquid can also be locked for long and unpredictable periods due to activation and exit queues, creating liquidity constraints and making it harder to meet redemptions. Because staking depends heavily on third-party providers, operational failures, outages, cybersecurity breaches, or mismanagement by these providers could lead to lost assets or reduced rewards. Rewards themselves are uncertain and can fluctuate based on network conditions, validator performance, governance changes, commission rates, and downtime. Additionally, staking may create conflicts of interest if operators are incentivized to stake more Ethereum, Solana, Polkadot, Sui, or Hyperliquid than is prudent, increasing liquidity risk.

Ethereum, Solana, Sui, Polkadot, and Hyperliquid are subject to unique and substantial risks, including significant price volatility, lack of liquidity, and theft. The value of an investment in any of the Trusts could decline significantly and without warning, including to zero. Ethereum, Solana, Sui, Polkadot, and Hyperliquid are subject to rapid price swings, including as a result of actions and statements by influencers and the media, changes in supply and demand, and other factors. There is no assurance that Ethereum, Solana, Sui, Polkadot, or Hyperliquid will maintain their value over the long-term.

Failure by a Trust’s Custodian to exercise due care in the safekeeping of the Trust’s underlying digital assets, as applicable, could result in a loss to the Trust. Shareholders cannot be assured that a Custodian will maintain adequate insurance with respect to the digital assets held by the custodian on behalf of the Trust.

The Trusts are not actively managed and will not take any actions to take advantage, or mitigate the impacts, of volatility in the price of their underlying digital assets, as applicable. An investment in a Trust is not a direct investment in Ethereum, Solana, Sui, Polkadot, or Hyperliquid. Investors will also forgo certain rights conferred by owning these digital assets directly. Shares of a Trust are generally bought and sold at market price (not NAV) and are not individually redeemed from the Trust. Only Authorized Participants may trade directly with a Trust and only in large blocks of Shares called “creation units.” Your brokerage commissions will reduce returns.

Shares in the Trusts are not FDIC insured, may lose value, and have no bank guarantee.

The Marketing Agent for each Trust is Foreside Global Services, LLC. 21shares US LLC is the Sponsor to each Trust. 21shares is not affiliated with Foreside Global Services, LLC. FalconX is not affiliated with Foreside Global Services, LLC.

© 2026 21shares US LLC. No part of this material may be reproduced in any form, or referred to in any other publication, without written permission.

###

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Aberdeen International Inc. – (“Aberdeen” or the “Company”) (TSX: AAB) reports, in accordance with the policies of the Toronto Stock Exchange, that the nominees listed in the management information circular dated August 28, 2026, for the 2026 annual general and special meeting of shareholders of Aberdeen held on September 28, 2026, (the “Meeting”) were elected as directors of the Company. Aberdeen management would like to thank shareholders for their participation and continuing support.

Detailed results of the vote for the election of directors held at the Meeting are set out below. A total of 50,050,225 common shares were voted in connection with the Meeting, representing approximately 31.146% of the issued and outstanding common shares of the Company.

Election of Directors

The shareholders approved the election as directors of the persons listed below, based on the following vote:

Nominee	Percentage of Votes For	Percentage of Votes Withheld
Fred Leigh	98.817%	1.183%
Gregory Biniowsky	67.441%	32.559%
Dev Shetty	67.249%	32.751%

Shareholders at the Meeting also (i) approved the appointment of McGovern Hurley LLP as the Company’s auditors, and (ii) set the number of directors at three (3).

The special resolution respecting a proposed consolidation of the Company’s common shares on the basis of up to 10 for one was not approved at the Meeting and was therefore revoked due to insufficient shareholder support.

ABOUT ABERDEEN INTERNATIONAL INC.

Aberdeen is a global resource investment company and merchant bank focused on small capitalization companies in the rare metals and renewable energy sectors.

For further information, please contact:

Dev Shetty
Executive Chairman and Chief Executive Officer
Aberdeen International Inc.
Dev.Shetty@aberdeen.green

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Giga Metals Corp. (TSX-V: GIGA; OTCQB: GIGGF; FSE: BRR2) (“Giga Metals” or the “Company”) today announced that effective September 28, 2026, and subject to the provisions of the Turnagain Joint Venture agreement dated August 15, 2022, Mitsubishi Corp (“Mitsubishi”) has elected to exercise its Put Right (“the Put”) and has agreed to sell its approximate 15% in the Turnagain Joint Venture back to Giga for nominal consideration. The Put and associated repurchase of the Joint Venture interest is anticipated to close on or around October 12, 2026.

“We would like to express our sincere appreciation for the opportunity to partner with Giga Metals on the Turnagain project since 2022” said Kota Ikenishi, General Manager of the Battery Minerals Department, Mitsubishi Corporation. “This decision is not a reflection of Turnagain, nor of the dedication, commitment, and hard work demonstrated by the Giga team. Rather, it is the result of Mitsubishi’s broader portfolio review and assessment of the North American nickel and EV markets since investment.”

“We want to thank Mitsubishi for its investment in the Turnagain project,” said Scott Lendrum, CEO of Giga Metals Corp. “Together, we completed a robust Pre-Feasibility study of our nickel/cobalt deposit in 2023. Since then, due to continued uncertainty in the nickel market, we have turned our attention to the copper exploration potential in the 80% of the Turnagain ultramafic system that remains unexplored or underexplored. A multi-phase exploration program is currently underway, guided by Dr. Stephen Beresford, with an emphasis on known copper mineralization and the significant potential of the Attic Zone.”

About Giga Metals Corporation
Giga Metals Corporation’s core asset is the Turnagain Project located in northern British Columbia, which contains one of the few significant undeveloped sulfide nickel and cobalt resources in the world. The Pre-Feasibility Study was released in October 2023. The Turnagain ultramafic complex is also prospective for copper, platinum and palladium mineralization in the Attic Zone, an area adjacent to the known nickel resource.

Qualified Person
Technical information herein has been reviewed and approved by Greg Ross, P.Geo. Mr. Ross is the Project Manager for Giga Metals and is a Qualified Person under NI 43-101.

Forward-looking Statements
Certain statements in this news release are forward-looking statements, which reflect the expectations of the Company. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such statements include, but are not limited to, completion of the Private Placement and any additional funding for the Turnagain Project. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: the conditions to closing of the Private Placement may be not be satisfied; the Company may not be able to locate suitable investors for the Private Placement and the terms for any additional funding of the Turnagain Project may not be finalized. These forward-looking statements are made as of the date of this news release and, except as required by applicable securities laws, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

On behalf of the Board of Directors of Giga Metals Corporation

“Scott Lendrum”

SCOTT LENDRUM, 
CEO & Director

Contact Information
Office Phone: +1 (604) 681-2300
Investor Inquiries: info@gigametals.com
Company Website: www.gigametals.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Suite 604 – 700 West Pender St., Vancouver, BC, Canada V6C 1G8

Hong Kong, Sept. 28, 2026 (GLOBE NEWSWIRE) — Magic Empire Global Limited (NASDAQ: MEGL) (the “Company”) today announced the pricing of a registered direct offering (the “Offering”) of 2,678,572 units (each a “Unit”) at an offering price of US$1.12 per Unit.

Each Unit consists of one Class A ordinary share of the Company, no par value (each, a “Class A Ordinary Share”) and one warrant to purchase one Class A Ordinary Share (or up to nine Class A Ordinary Shares pursuant to the alternative cashless exercise (zero exercise price option) (each, a “Warrant”). Each Warrant will have an exercise price of US$1.12 per Class A Ordinary Share and will be exercisable beginning on the issuance date and ending on the one-year anniversary of the issuance date.

The Company expects to receive aggregate gross proceeds of US$3 million from the Offering, before deducting placement agent commissions and other estimated expenses payable by the Company, excluding the exercise of any Warrant offered.

The Offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this Offering for working capital and general corporate purposes.

Chaince Securities, LLC is acting as the Sole Placement Agent for the Offering.

The securities described above are being offered by the Company pursuant to a registration statement on Form F-3 (File No. 333-298796), as amended, previously filed and declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus forming part of the effective registration statement. A final prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, from Chaince Securities, LLC at info@chaincesecurities.com.

About Magic Empire Global Limited

Established in 2016, Magic Empire Global Limited is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services. Its service offerings mainly comprise (i) IPO sponsorship services; (ii) financial advisory and independent financial advisory services; (iii) compliance advisory services; and (iv) corporate services. For more information, please visit the Company’s website at https://www.meglmagic.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Chaince Securities, LLC

1251 Avenue of the Americas, 41st Floor
New York, NY 10020
www.chaincesecurities.com
info@chaincesecurities.com

Magic Empire Global Limited

Suite 5A, 15/F, Sino Plaza
255-257 Gloucester Road
Causeway Bay, Hong Kong
Main Phone: + 852 2889 8778
www.meglmagic.com
Wangmei@megltech.com

Five Executives and Directors Purchased 815,000 ATCH Shares with Personal Funds

TAMPA, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that five members of its executive leadership and Board of Directors purchased an aggregate of 815,000 shares of the Company’s common stock with their personal funds in transactions executed on September 24 and 25, 2026.

According to Form 4s filed with the U.S. Securities and Exchange Commission on September 28, the reporting persons were Executive Chairman John Schaible (100,000 shares); President Craig Ridenhour (100,000 shares); Chief Financial Officer and General Counsel Sandip Patel (100,000 shares); and directors Thomas Jon Hammond (500,000 shares) and Steven J. Carlson (15,000 shares). The aggregate transaction value was approximately $162,500, calculated using the prices reported in the filings. The shares were purchased by these individuals and were not awarded to them by the Company.

“These purchases reflect our confidence in AtlasClear and our continued alignment with AtlasClear shareholders as we execute on the Company’s strategic objectives,” said John Schaible, Executive Chairman. “Members of our leadership team and Board are shareholders alongside our investors, and we remain focused on building the business and creating long-term shareholder value.”

The Form 4s originally filed on September 28 contained an incorrect transaction code for the purchases, which initially coded the transactions as acquired as if granted to the directors by the Company. The amended Form 4s indicating the shares being acquired in open market purchases have been filed with the SEC as of this release.

About AtlasClear Holdings, Inc.
AtlasClear Holdings, Inc. (NYSE American: ATCH) is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear seeks to deliver a vertically integrated suite of brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

To stay up to date on AtlasClear’s platform strategy and market perspective, subscribe to the Company’s YouTube channel and watch the Clearing the View by AtlasClear video series

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements in this communication may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions.

Forward-looking statements include, but are not limited to, statements regarding expected future growth
These statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control, and actual results may differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to: the Company’s failure to enter into definitive agreements with the digital asset business or the Dawson James parties, or its failure to complete the proposed acquisitions on favorable terms or at all; failure to receive the required regulatory approvals for the proposed acquisitions, including the acquisition of Commercial Bancorp of Wyoming; the Company’s inability to integrate, and to realize the benefits of, the proposed acquisitions; delays in onboarding correspondent broker-dealers or the failure of correspondent relationships to generate the anticipated revenue; changes in general economic or political conditions; changes in the markets that AtlasClear targets; slowdowns in securities or digital asset trading or shifting demand for trading, clearing and settling financial products; and any change in laws applicable to AtlasClear or any regulatory or judicial interpretation thereof. For additional information regarding risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026. AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact:
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact:
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) will announce its 2026 third quarter results at 6:00 a.m. Central Daylight Time (“CDT”) on Wednesday, October 28, 2026. This announcement will be followed by an earnings conference call webcast at 7:30 a.m. CDT.

For listeners who wish to participate in the question and answer session via telephone, please pre-register at Kirby Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. To listen to the webcast, please visit the Investor Relations section of Kirby’s website at www.kirbycorp.com. A replay of the webcast will be available for a period of one year by visiting the Investor Relations section of Kirby’s website.

The financial and other information to be discussed in the conference call will be available in the 2026 third quarter press release and in a Form 8-K to be posted prior to the call on Kirby’s website at www.kirbycorp.com.

Kirby Corporation, based in Houston, Texas, is the nation’s largest domestic tank barge operator, transporting bulk liquid products throughout the Mississippi River System, on the Gulf Intracoastal Waterway, and coastwise along all three United States coasts. Kirby transports petrochemicals, black oil, refined petroleum products, and agricultural chemicals by tank barge. In addition, Kirby participates in the transportation of dry-bulk commodities in United States coastwise trade. Through the distribution and services segment, Kirby provides equipment, after-market parts and services for power generation systems in applications that include behind the meter power systems and emergency backup systems, after-market and genuine replacement parts and services for engines, transmissions, reduction gears, electric motors, drives, and controls, specialized electrical distribution and controls systems, and related equipment used in power generation, marine, on-highway, oilfield services, and other industrial applications. Kirby also rents equipment including generators, industrial compressors, high-capacity lift trucks, construction equipment and refrigeration trailers for use in a variety of industrial markets. Kirby also manufactures and remanufactures specialized equipment, including pressure pumping units and electric fracturing systems, electric power generation equipment, and specialized electrical distribution and control equipment for data centers, oilfield service, railroad and other industrial customers.

CONTACT: Contact: Donny Chia
713-435-1077